Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma : From Dose Puzzle to Pharmacogenomic Biomarkers
Cytarabine is a pyrimidine nucleoside analog, commonly used in multiagent chemotherapy regimens for the treatment of leukemia and lymphoma, as well as for neoplastic meningitis. Ara-C-based chemotherapy regimens can induce a suboptimal clinical outcome in a fraction of patients. Several studies suggest that the individual variability in clinical response to Leukemia & Lymphoma treatments among patients, underlying either Ara-C mechanism resistance or toxicity, appears to be associated with the intracellular accumulation and retention of Ara-CTP due to genetic variants related to metabolic enzymes. Herein, we reported (a) the latest Pharmacogenomics biomarkers associated with the response to cytarabine and (b) the new drug formulations with optimized pharmacokinetics. The purpose of this review is to provide readers with detailed and comprehensive information on the effects of Ara-C-based therapies, from biological to clinical practice, maintaining high the interest of both researcher and clinical hematologist. This review could help clinicians in predicting the response to cytarabine-based treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancers - 13(2021), 5 vom: 25. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Francia, Raffaele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ara-C |
|---|
| Anmerkungen: |
Date Revised 17.03.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers13050966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322263492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322263492 | ||
| 003 | DE-627 | ||
| 005 | 20231225181653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13050966 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322263492 | ||
| 035 | |a (NLM)33669053 | ||
| 035 | |a (PII)966 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Francia, Raffaele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma |b From Dose Puzzle to Pharmacogenomic Biomarkers |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.03.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Cytarabine is a pyrimidine nucleoside analog, commonly used in multiagent chemotherapy regimens for the treatment of leukemia and lymphoma, as well as for neoplastic meningitis. Ara-C-based chemotherapy regimens can induce a suboptimal clinical outcome in a fraction of patients. Several studies suggest that the individual variability in clinical response to Leukemia & Lymphoma treatments among patients, underlying either Ara-C mechanism resistance or toxicity, appears to be associated with the intracellular accumulation and retention of Ara-CTP due to genetic variants related to metabolic enzymes. Herein, we reported (a) the latest Pharmacogenomics biomarkers associated with the response to cytarabine and (b) the new drug formulations with optimized pharmacokinetics. The purpose of this review is to provide readers with detailed and comprehensive information on the effects of Ara-C-based therapies, from biological to clinical practice, maintaining high the interest of both researcher and clinical hematologist. This review could help clinicians in predicting the response to cytarabine-based treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ara-C | |
| 650 | 4 | |a mechanism of resistance | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a target therapy | |
| 700 | 1 | |a Crisci, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a De Monaco, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Cafiero, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Re, Agnese |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccarino, Giancarla |e verfasserin |4 aut | |
| 700 | 1 | |a De Filippi, Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Frigeri, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Corazzelli, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Micera, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 13(2021), 5 vom: 25. Feb. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:5 |g day:25 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers13050966 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 5 |b 25 |c 02 | ||